Research Analysts Offer Predictions for MRK FY2025 Earnings

Merck & Co., Inc. (NYSE:MRK) – Investment analysts at Leerink Partnrs raised their FY2025 earnings estimates for Merck & Co., Inc. in a research note issued to investors on Monday, November 10th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings per share of $9.07 for the year, up from their prior estimate of $8.79. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $9.01 per share. Leerink Partnrs also issued estimates for Merck & Co., Inc.’s Q1 2026 earnings at $2.08 EPS, Q2 2026 earnings at $2.06 EPS and FY2027 earnings at $9.13 EPS.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, October 30th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.22. The business had revenue of $17.28 billion during the quarter, compared to analyst estimates of $17 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The company’s revenue was up 3.7% compared to the same quarter last year. During the same period last year, the company posted $1.57 EPS. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS.

MRK has been the subject of a number of other reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Morgan Stanley raised their price objective on shares of Merck & Co., Inc. from $98.00 to $100.00 and gave the stock an “equal weight” rating in a research note on Monday, November 3rd. Wells Fargo & Company cut their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 30th. Citigroup started coverage on Merck & Co., Inc. in a report on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price for the company. Finally, Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their price target for the company from $100.00 to $90.00 in a report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $104.47.

Merck & Co., Inc. Trading Up 4.8%

Shares of NYSE MRK opened at $90.91 on Wednesday. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $105.07. The company has a market cap of $225.64 billion, a price-to-earnings ratio of 14.01, a P/E/G ratio of 0.95 and a beta of 0.34. The business has a fifty day simple moving average of $84.76 and a 200-day simple moving average of $82.19.

Insider Buying and Selling

In other news, EVP David Michael Williams sold 8,614 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $83.59, for a total transaction of $720,044.26. Following the transaction, the executive vice president owned 24,578 shares in the company, valued at approximately $2,054,475.02. This trade represents a 25.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

Large investors have recently bought and sold shares of the stock. Legend Financial Advisors Inc. acquired a new position in shares of Merck & Co., Inc. during the second quarter valued at about $25,000. Darwin Wealth Management LLC lifted its position in shares of Merck & Co., Inc. by 237.4% in the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after acquiring an additional 216 shares during the period. Kilter Group LLC bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter worth approximately $27,000. Bare Financial Services Inc grew its holdings in shares of Merck & Co., Inc. by 51.9% during the 2nd quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock worth $29,000 after purchasing an additional 125 shares in the last quarter. Finally, Barnes Dennig Private Wealth Management LLC increased its position in shares of Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after purchasing an additional 266 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.